Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov) - Aug 7, 2020 - P1/2 | N=86 | Not yet recruiting | Sponsor: German Cancer Research Center
Checkpoint inhibition • First-in-human • New P1/2 trial • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • FOLH1
|